127 filings
Page 5 of 7
8-K
wt6s4et
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
wvitv3zgwtn
21 Mar 22
Departure of Directors or Certain Officers
6:32am
8-K/A
mwg6w6
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
n53mkq6
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
xlnsjdki6yc0cy
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
1sp2do3fv5n 4jy6ewf
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
xo0ug1
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
dpm5 vcbjb7
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
9bj7lo tahy
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
j6b93ecvixve37oa
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
ra7x1h8af 31tm6
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
dogyab 565152
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
zxo6lz
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
9j0cvijz6
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
1dn6k7
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
10-Q
q7j9wf24qg
20 Sep 21
Quarterly report
4:17pm
8-K
qtbo ly2nfbyj
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
7wfy m02h7253r
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
S-8
qkpl409o6r3qb4s3dff
23 Aug 21
Registration of securities for employees
4:35pm